Who
Kevin Patrick Moran
SVP, CFO & Treasurer
Company insider
Files Form 4 as: SVP, CFO & Treasurer, Vanda Pharmaceuticals.
In numbers
- Trades disclosed
- 33
- Buys
- 1
- Sells
- 15
- Bought
- $8,780
- Sold
- $1.4M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 27 Jul 2020
- Last trade
- 2 Mar 2026
- Last filed
- 4 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Mar 2026filed 4 Mar 2026 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $351K42,442 at $8.27 | filing |
| 2 Mar 2026filed 4 Mar 2026 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $351K42,442 at $8.27 | filing |
| 18 Feb 2026filed 19 Feb 2026 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 18 Feb 2026filed 19 Feb 2026 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 1 Mar 2025filed 4 Mar 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $128K26,941 at $4.76 | filing |
| 21 Feb 2025filed 24 Feb 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Bought | $8,7802,000 at $4.39 | filing |
| 18 Feb 2025filed 20 Feb 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 29 Jul 2024filed 29 Jul 2024 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $13K2,251 at $5.92 | filing |
| 5 Mar 2024filed 6 Mar 2024 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $37K8,902 at $4.20 | filing |
| 4 Mar 2024filed 6 Mar 2024 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $26K5,798 at $4.48 | filing |
| 16 Feb 2024filed 21 Feb 2024 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 28 Jul 2023filed 1 Aug 2023 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $2,596412 at $6.30 | filing |
| 28 Jul 2023filed 1 Aug 2023 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $11K1,800 at $6.31 | filing |
| 15 Jun 2023filed 20 Jun 2023 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $101K16,000 at $6.29 | filing |
| 3 Mar 2023filed 6 Mar 2023 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $37K5,968 at $6.28 | filing |
| 2 Mar 2023filed 6 Mar 2023 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $50K7,966 at $6.26 | filing |
| 16 Feb 2023filed 21 Feb 2023 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —77,500 at $0.00 | filing |
| 16 Feb 2023filed 21 Feb 2023 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —32,700 at $0.00 | filing |
| 6 Dec 2022filed 7 Dec 2022 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 6 Dec 2022filed 7 Dec 2022 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $23K7,500 at $3.12 | filing |
News
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development ProgramVNDA · prnewswire.com · 14 Oct 2026
0 headlines in the last 90 days name Kevin Patrick Moran; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.